SCHEMBL641152

SCHEMBL641152

O=C(Cn1c(=O)[nH]c2ccc(Cl)cc21)N1CCN(c2ccncc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 1/20 0.48
GRM5 P41594 1/20 0.47
MAPT P10636 5/20 0.47
POLB P06746 2/20 0.46
AKR1C3 P42330 1/20 0.46
CXCR3 P49682 1/20 0.46
KCNH2 Q12809 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CBX7 O95931 1/20 0.45
CDYL2 Q8N8U2 1/20 0.45
CDYL Q9Y232 1/20 0.45
CDY1; CDY1B Q9Y6F8 1/20 0.45
DAO P14920 1/20 0.45
TP53 P04637 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640059 0.87 SMN1; SMN2 (0.46) MAPTCXCR3KCNH2ALDH1A1SMN1; SMN2
SCHEMBL3066761 0.81 CCR1 (0.55) MAPTPOLBKCNH2SMN1; SMN2CBX7
SCHEMBL640092 0.77 AKR1C3 (0.45) F10MAPTAKR1C3TRPV1DAO
SCHEMBL641842 0.76 MAPT (0.52) MAPTPOLBAKR1C3ALDH1A1TRPV1
SCHEMBL640665 0.74 LMNA (0.43) F10POLBAKR1C3TRPV1DAO
SCHEMBL640508 0.74 CBX7 (0.58) CBX7CDYL2CDYLCDY1; CDY1BDAO
SCHEMBL3067164 0.73 CCR1 (0.55) MAPTPOLBKCNH2SMN1; SMN2
SCHEMBL3063228 0.72 EPHX2 (0.41) CBX7CDYL2CDYLCDY1; CDY1BDAO
SCHEMBL17938733 0.71 KMT2A (0.71) MAPTPOLBAKR1C3MEN1KMT2A
SCHEMBL641515 0.71 F10 (0.47) F10GRM5POLBAKR1C3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791148-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-29 US disclosed
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2012-07-05 US disclosed
US-8119676-B2 Substituted benzimidazolone derivatives, medicaments comprising them and their use Abbott GmbH & Co. HG (DE) 2012-02-21 US disclosed
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2010-06-17 US disclosed
EP-2061769-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE Abbott GmbH & Co. KG (DE) 2009-05-27 EP disclosed
WO-2008025736-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE ABBOTT GMBH & CO. KG (DE) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152168-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A F10 276/4885GRM5 2845/4885MAPT 4368/4885
US-20120172335-A1 SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE AVPR2, AVPR1B, AVPR1A F10 276/4885GRM5 2845/4885MAPT 4368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.